Ren Yongjun, Zhao Caixia, He Yi, Min Xuli, Xu Hao, Hu Xiao
Department of Interventional Radiology, Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China.
Department of Oncology, Nanchong Central Hospital, Nanchong, Sichuan, 637000, People's Republic of China.
Onco Targets Ther. 2021 Oct 12;14:5035-5043. doi: 10.2147/OTT.S304494. eCollection 2021.
It was reported that long-noncoding RNAs (lncRNAs) had been identified as a novel class of regulators related to various cancers. RPARP-AS1, a differentially-expressed gene, was found in analysis of the gene expression profile of CRC from GEO database. However, its function has not been clear.
RPARP-AS1 expression was determined by qPCR and Startbase3 analysis. Knockdown of RPARP-AS1 in CRC cell lines was performed by RNAi technology, named si-RPARP-AS1 HCT116 and si-RPARP-AS1 LoVo. Cell proliferation was examined by CCK8 and colony formation assay. RNA pull-down and Luciferase reporter assay were performed to confirm the interaction between RPARP-AS1 and miR-125a-5p.
In the study, we found that the expression of RPARP-AS1 was significantly up-regulated in CRC tissues and multiple CRC cell lines, which was closely related to poor prognosis of CRC patients. Loss-of-function studies indicated that knockdown of RPARP-AS1 inhibited CRC cell proliferation, migration and invasion in HCT116 and LoVo cell lines. Results of research on the mechanisms showed that RPARP-AS1 functioned as a competitive endogenous RNA (ceRNA) to sponge miR-125a-5p, therefore promoting CRC procession.
In summary, these results indicated that RPARP-AS1/miR-125a-5p axis played a positive role in promoting cell proliferation, migration and invasion in CC. It may be as a biomarker used to evaluate CRC prognosis.
据报道，长链非编码RNA（lncRNAs）已被鉴定为一类与多种癌症相关的新型调节因子。在对来自基因表达综合数据库（GEO）的结直肠癌基因表达谱分析中发现了差异表达基因RPARP-AS1。然而，其功能尚不清楚。
通过定量聚合酶链反应（qPCR）和Startbase3分析确定RPARP-AS1的表达。采用RNA干扰技术在结直肠癌细胞系中敲低RPARP-AS1，命名为si-RPARP-AS1 HCT116和si-RPARP-AS1 LoVo。通过细胞计数试剂盒8（CCK8）和集落形成试验检测细胞增殖。进行RNA下拉和荧光素酶报告基因试验以证实RPARP-AS1与miR-125a-5p之间的相互作用。
在本研究中，我们发现RPARP-AS1在结直肠癌组织和多个结直肠癌细胞系中表达显著上调，这与结直肠癌患者的不良预后密切相关。功能丧失研究表明，敲低RPARP-AS1可抑制HCT116和LoVo细胞系中的结直肠癌细胞增殖、迁移和侵袭。机制研究结果表明，RPARP-AS1作为竞争性内源性RNA（ceRNA）发挥作用，可吸附miR-125a-5p，从而促进结直肠癌进展。
总之，这些结果表明RPARP-AS1/miR-125a-5p轴在促进结直肠癌细胞增殖、迁移和侵袭中起积极作用。它可能作为评估结直肠癌预后的生物标志物。
